DeuterOncology Maryland

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation studyTumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholdsDO-2 has a very good safety profile with minimal peripheral oedema and clean safety profile compared to competitorsView original content:https://www.prnewswire.co.uk/news-releases/deuteroncology-to-present-promising-phase-i-do-2-met-kinase-inhibitor-data-at-wclc-2025-302549690.html